1-(((6-Methylpyridin-3-yl)oxy)methyl)cyclopropanamine | 959957-86-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(((6-Methylpyridin-3-yl)oxy)methyl)cyclopropanamine
• 英文别名: 1-[(6-methylpyridin-3-yl)oxymethyl]cyclopropan-1-amine
• CAS: 959957-86-9
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: CZTGYKBKXXBOFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 1-(((6-Methylpyridin-3-yl)oxy)methyl)cyclopropanamine
  参考文献：
  名称：

  Preparation and affinity profile of novel nicotinic ligands

  摘要：

  Novel nicotinic ligands, characterized by the presence of an amino substituted cyclopropane ring connected to a pyridine nucleus, are described. Pharmacological investigation revealed that these compounds exhibit highest affinity for the rat alpha 4 beta 2 subtype of the nicotinic receptor with no affinity for the muscarinic receptor. No appreciable affinity for the muscular or for the ganglionic nicotinic receptor was observed at concentrations up to 10 mu M. The increase in cortical ACh release as well as a positive effect on memory in a social recognition test in rat are exemplified. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.075

文献信息

• PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Teijin Pharma Limited

  公开号：EP3305785A1

  公开（公告）日：2018-04-11

  The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

  本发明的目的是提供一种具有优异 CDK4/6 抑制活性的化合物。本发明是通式（I）代表的化合物或其药学上可接受的盐。
• Preparation and affinity profile of novel nicotinic ligands
  作者：Yves Charton、Claude Guillonneau、Brian Lockhart、Pierre Lestage、Solo Goldstein

  DOI：10.1016/j.bmcl.2007.12.075

  日期：2008.3

  Novel nicotinic ligands, characterized by the presence of an amino substituted cyclopropane ring connected to a pyridine nucleus, are described. Pharmacological investigation revealed that these compounds exhibit highest affinity for the rat alpha 4 beta 2 subtype of the nicotinic receptor with no affinity for the muscarinic receptor. No appreciable affinity for the muscular or for the ganglionic nicotinic receptor was observed at concentrations up to 10 mu M. The increase in cortical ACh release as well as a positive effect on memory in a social recognition test in rat are exemplified. (C) 2008 Elsevier Ltd. All rights reserved.